"Groundbreaking Research Challenges Molecular Neuroscience Principles"

Researchers have made a paradigm-shifting discovery in molecular neuroscience, finding that learning and memory rely on the structural, not enzymatic, functions of the CaMKII enzyme. This breakthrough could lead to new treatments for Alzheimer's and potentially Down syndrome by targeting the enzyme's enzymatic activity without affecting memory and learning. The findings challenge previous beliefs and open the door to the therapeutic use of inhibitors that specifically target the enzymatic activity of CaMKII. The researchers are now testing whether these inhibitors can be harnessed for human therapy.